Epidemiological characteristics of hepatitis B and C in patients with inflammatory arthritis: Implications from treasure database

Basit Öğe Kaydı
dc.authoridBilgin, Emre/0000-0002-2260-4660
dc.authoridErden, Abdulsamet/0000-0002-8084-2018
dc.authoridBadak, Suade ozlem/0000-0002-4661-787X
dc.authoridEKICI, MUSTAFA/0000-0002-8757-6226
dc.authorwosidBilgin, Emre/C-8092-2015
dc.authorwosidErden, Abdulsamet/W-2397-2019
dc.contributor.authorErsozlu, Emine Duygu
dc.contributor.authorEkici, Mustafa
dc.contributor.authorCoskun, Belkis Nihan
dc.contributor.authorBadak, Suade Ozlem
dc.contributor.authorBilgin, Emre
dc.contributor.authorKalyoncu, Umut
dc.contributor.authorYagiz, Burcu
dc.date.accessioned2024-06-12T11:02:56Z
dc.date.available2024-06-12T11:02:56Z
dc.date.issued2023
dc.departmentTrakya Üniversitesien_US
dc.description.abstractObjectives: This study aimed to evaluate the hepatitis B (HBV) and C (HCV) frequency and clinical characteristics among patients with rheumatoid arthritis (RA) or spondyloarthritis (SpA) who receive biological treatments.Patients and methods: The observational study was conducted with patients from the TReasure database, a web-based prospective observational registry collecting data from 17 centers across Turkiye, between December 2017 and June 2021. From this database, 3,147 RA patients (2,502 males, 645 females; median age 56 years; range, 44 to 64 years) and 6,071 SpA patients (2,709 males, 3,362 females; median age 43 years; range, 36 to 52 years) were analyzed in terms of viral hepatitis, patient characteristics, and treatments used.Results: The screening rate for HBV was 97% in RA and 94.2% in SpA patients. Hepatitis B surface antigen (HBsAg) positivity rates were 2.6% and 2%, hepatitis B surface antibody positivity rates were 32.3% and 34%, hepatitis B core antibody positivity rates were 20.3% and 12.5%, HBV DNA (deoxyribonucleic acid) positivity rates were 3.5% and 12.5%, and antibody against HCV positivity rates were 0.8% and 0.3% in RA and SpA patients, respectively. The HBsAg-positive patients were older and had more comorbidities, including hypertension, diabetes, and coronary artery disease. In addition, rheumatoid factor (RF) positivity was more common in HBsAg-positive cases. The most frequently prescribed biologic disease-modifying antirheumatic drugs were adalimumab (28.5%), etanercept (27%), tofacitinib (23.4%), and tocilizumab (21.5%) in the RA group and adalimumab (48.1%), etanercept (31.4%), infliximab (22.6%), and certolizumab (21.1%) in the SpA group. Hepatitis B reactivation was observed in one RA patient during treatment, who received rituximab and prophylaxis with tenofovir.Conclusion: The epidemiological characteristics of patients with rheumatic diseases and viral hepatitis are essential for effective patient management. This study provided the most recent epidemiological characteristics from the prospective TReasure database, one of the comprehensive registries in rheumatology practice.en_US
dc.identifier.doi10.46497/ArchRheumatol.2023.9504
dc.identifier.endpage357en_US
dc.identifier.issn2618-6500
dc.identifier.issue3en_US
dc.identifier.pmid38046251en_US
dc.identifier.scopus2-s2.0-85175151998en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage347en_US
dc.identifier.urihttps://doi.org/10.46497/ArchRheumatol.2023.9504
dc.identifier.urihttps://hdl.handle.net/20.500.14551/21474
dc.identifier.volume38en_US
dc.identifier.wosWOS:001108061700012en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTurkish League Against Rheumatismen_US
dc.relation.ispartofArchives Of Rheumatologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHBVen_US
dc.subjectHCVen_US
dc.subjectRheumatic Diseasesen_US
dc.subjectRheumatoid Arthritisen_US
dc.subjectSpondyloarthritisen_US
dc.subjectTreasureen_US
dc.subjectViral Hepatitisen_US
dc.subjectViral Reactivationen_US
dc.subjectSociety Classification Criteriaen_US
dc.subjectRheumatoid-Arthritisen_US
dc.subjectAnkylosing-Spondylitisen_US
dc.subjectReactivationen_US
dc.subjectSpondyloarthritisen_US
dc.subjectInfectionsen_US
dc.subjectPrevalenceen_US
dc.subjectManagementen_US
dc.subjectUpdateen_US
dc.subjectRisken_US
dc.titleEpidemiological characteristics of hepatitis B and C in patients with inflammatory arthritis: Implications from treasure databaseen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu